Compare Huntington Bancshares Incorporated (HBAN) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs 10X Genomics Inc — how do they compare? Huntington Bancshares Incorporated trades at $17.77 (market cap $35.93B), while 10X Genomics Inc trades at $58.47 (market cap $7.61B). The key difference: Huntington Bancshares Incorporated is far larger — about 4.7× 10X Genomics Inc's market cap, and Huntington Bancshares Incorporated pays a 3.49% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| HBAN | TXG | |
|---|---|---|
Market Cap | $35.93B | $7.61B |
Sector | Financials | Health |
52-Week High | $19.27 | $58.57 |
52-Week Low | $15.02 | $11.34 |
Dividend Yield | 3.49% | — |
Enterprise Value | — | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HBAN trades at $17.85, up 1.42% today, with a bullish technical signal from moving averages and a consensus price target of $19.78. Recent Q2 2026 earnings matched estimates, with revenue growth and net interest income rising year-over-year. The company targets an 18-19% ROTCE by 2027, supported by efficiency gains and capital returns. However, rising deposit costs and mixed quarterly EPS results present near-term challenges.
The outlook for HBAN is cautiously optimistic, with potential upside from strategic growth initiatives and a reasonable P/E of 13.68. Risks include margin pressure from higher funding costs and volatile earnings performance. Analyst sentiment is balanced, with 44.68% buy ratings, but investors should monitor expense management and loan growth sustainability.
TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
